A number of global ‘mega-trends’, such as dated technology and manufacturing inefficiencies, present major challenges for the drug industry, according to Dave Tudor
Chinese investors are looking abroad for technology that will provide short-term returns and long-term health benefits to its large patient population, according to Panacea Ventures partner.
The second phase of Changzhou Qianhong Bio-pharma manufacturing project sees a further ¥1 billion devoted to increasing tablet and injection production.
A prequalification pilot designed to assess biosimilar versions of Roche’s Rituxan and Herceptin has attracted global interest from manufacturers, says WHO executive.
As an increasing number of biosimilar developers target the European market, lesser-known firms may explore alternative commercialisation strategies, says Iqvia executive.
MSD announced that the EMA’s CHMP has adopted a positive opinion recommending approval of Keytruda as an adjuvant therapy for the treatment of patients with melanoma.
Sarepta Therapeutics signed a long-term, strategic manufacturing partnership with Paragon Bioservices to produce micro-dystrophin to grow its gene therapy program.
CBMG announced a manufacturing collaboration agreement with Novartis at the end of last month to produce CAR-T treatment Kymriah for the Chinese market and the company has further ambitions in the pipeline.
Provisional results from a survey evaluating the reputations of major biopharmaceutical countries indicate the US, Germany and Japan are regarded as ‘tier one’ nations, followed closely by Sweden and the UK.
